We were thrilled to attend the World Evidence, Pricing and Access Congress (World EPA) in Amsterdam on March 5-6, 2025. The event provided essential insights into the evolving global market access landscape, emphasising critical developments in Rare Diseases, Market Access, and Health Technology Assessment (HTA). Key discussions highlighted ongoing uncertainties around the EU JCA, the strategic role of AI in enhancing Real-World Evidence (RWE), and shifts in reimbursement processes affecting patient access.
Our research poster
Poster: “Evaluating the capabilities of AI tools for extracting pricing and reimbursement insights”
This study compares the effectiveness and accuracy of ChatGPT to human researchers (HR) in analysing the evaluation and reimbursement of digital therapeutics. It evaluates ChatGPT’s reliability as a tool for insight extraction in healthcare P&R research in terms of replicating the outcomes from a 2023 ISPOR research poster using targeted prompts.
Read More Here
Our presentation
“How to navigate early payer scientific advice: a BRAVE perspective”
Charlie Hewitt from Remap Consulting delivered a presentation on “How to Navigate Early Payer Scientific Advice: A BRAVE Perspective.” He discussed effective strategies for navigating early payer scientific advice to optimise asset outcomes, highlighted the variations across different advisory processes, and emphasized key considerations manufacturers should account for.
For more information about his presentation
Insights
Just like in past years, Remap Consulting crafted daily summaries of the essential conference topics, including the plenary sessions.